{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:35:33Z","timestamp":1789472133361,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid cancer has incidence continues to rise globally. Understanding the epidemiology of thyroid cancer and the future burden on public health systems is necessary. We aimed to investigate the prevalence, incidence, and mortality of thyroid cancer by age, sex, country in Asia in 2020 and its projection up to 2040.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Global Cancer Observatory provided data on thyroid cancer incidence and mortality for the year 2020. By taking into account the sex, age group, and Asia region, the counts, rates, and mortality-to-incidence ratios (MIRs) were calculated. To estimate the projected number of new cancer cases or mortalities between 2025 and 2040 in a particular nation, the corresponding expected population for the years 2025 to 2040 was multiplied by the age-specific incidence or mortality rates calculated for 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 2020, the 5-year prevalence rate, age-standardized incidence rate (ASIR), and age-standardized mortality rate (ASMR) for thyroid cancer were 24.60, 6.40, and 0.44 per 100,000 population in Asia, respectively. By country, the highest thyroid cancer 5-year prevalence rates and ASIRs were found in the Republic of Korea. The highest thyroid cancer ASMRs among both sexes combined were in the United Arab Emirates and Syrian Arab Republic. The highest incidence and mortality crude rates were in the 50\u201359 and 70\u2009+\u2009age groups, respectively. Women had higher incidence and mortality rates than men. There were significant correlations between human development index and MIR and ASIR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The number of newly diagnosed thyroid cancer cases and mortalities are expected to rise by 26.6% and 77.8% up to 2040 in Asia, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Asia is experiencing rising rates of thyroid cancer incidence and mortality. It is imperative to prioritize strategies aimed at high-incidence regions, transitioning countries with limited resources, and younger adult populations to alleviate the global burden of thyroid cancer and resolve disparities in cancer management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-24029-9","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:35:47Z","timestamp":1759232147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Epidemiology of thyroid cancer in Asia in 2020 and its projection to 2040"],"prefix":"10.1186","volume":"25","author":[{"given":"Seyed Ehsan","family":"Mousavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Abiri Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia","family":"Motlagh Asghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Aria","family":"Nejadghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"4 Suppl 4","key":"24029_CR1","first-page":"3","volume":"13","author":"JP Shah","year":"2015","unstructured":"Shah JP. Thyroid carcinoma: epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol. 2015;13(4 Suppl 4):3\u20136.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"24029_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","volume":"10","author":"M Pizzato","year":"2022","unstructured":"Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):264\u201372.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"24029_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"24029_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3803\/EnM.2022.1553","volume":"37","author":"CK Jung","year":"2022","unstructured":"Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach. Endocrinol Metab. 2022;37(5):703\u201318.","journal-title":"Endocrinol Metab"},{"issue":"3","key":"24029_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ejso.2017.05.002","volume":"44","author":"B Xu","year":"2018","unstructured":"Xu B, Ghossein R. Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management. Eur J Surg Oncol. 2018;44(3):338\u201347.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"24029_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s12276-022-00740-0","volume":"54","author":"J Park","year":"2022","unstructured":"Park J, Kim D, Lee J-O, Park H-C, Ryu BY, Kim JH, et al. Dissection of molecular and histological subtypes of papillary thyroid cancer using alternative splicing profiles. Exp Mol Med. 2022;54(3):263\u201372.","journal-title":"Exp Mol Med"},{"issue":"1","key":"24029_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MNM.0000000000001304","volume":"42","author":"SA Schenke","year":"2021","unstructured":"Schenke SA, Klett R, Wagner P-R, Mott S, Zimny M, Feek U, et al. Characteristics of different histological subtypes of thyroid nodules classified with 99mTc-methoxy-isobutyl-isonitrile imaging and thyroid imaging reporting and data system. Nucl Med Commun. 2021;42(1):73\u201380.","journal-title":"Nucl Med Commun"},{"key":"24029_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13044-015-0020-8","volume":"8","author":"MB Zimmermann","year":"2015","unstructured":"Zimmermann MB, Galetti V. Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies. Thyroid Res. 2015;8:8.","journal-title":"Thyroid Res"},{"key":"24029_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.622085","author":"C Lv","year":"2021","unstructured":"Lv C, Gao Y, Yao J, Li Y, Lou Q, Zhang M, et al. High iodine induces the proliferation of papillary and anaplastic thyroid cancer cells via AKT\/Wee1\/CDK1 axis. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.622085.","journal-title":"Front Oncol"},{"issue":"4","key":"24029_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4183\/aeb.2018.525","volume":"14","author":"H Gharib","year":"2018","unstructured":"Gharib H. Does iodine cause thyroid cancer? Acta Endocrinologica (Bucharest). 2018;14(4):525\u20136.","journal-title":"Acta Endocrinologica (Bucharest)"},{"issue":"2","key":"24029_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/2473974X18777238","volume":"2","author":"LL Sakafu","year":"2018","unstructured":"Sakafu LL, Mselle TF, Mwaiselage JD, Maunda KK, Eddin BS, Zafereo ME. Thyroid cancer and iodine deficiency status: a 10-year review at a single cancer center in Tanzania. OTO Open. 2018;2(2): 2473974X18777238.","journal-title":"OTO Open"},{"issue":"11","key":"24029_CR12","doi-asserted-by":"publisher","first-page":"e22490","DOI":"10.1016\/j.heliyon.2023.e22490","volume":"9","author":"J Chen","year":"2023","unstructured":"Chen J, Wang C, Shao B. Global, regional, and national thyroid cancer age-period-cohort modeling and Bayesian predictive modeling studies: a systematic analysis of the Global Burden of Disease Study 2019. Heliyon. 2023;9(11):e22490.","journal-title":"Heliyon"},{"issue":"4","key":"24029_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/geographies2040035","volume":"2","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang W, Li P, Qi X, Hu W. Risk analysis of thyroid cancer in China: a spatial analysis. Geographies. 2022;2(4):577\u201392.","journal-title":"Geographies"},{"issue":"2","key":"24029_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12020-023-03408-5","volume":"82","author":"S Hassanipour","year":"2023","unstructured":"Hassanipour S, Zare R, Shahedi A, Delam H. Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study. Endocrine. 2023;82(2):237\u201349.","journal-title":"Endocrine"},{"issue":"11","key":"24029_CR15","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2217\/fon.10.127","volume":"6","author":"R Rahbari","year":"2010","unstructured":"Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771\u20139.","journal-title":"Future Oncol"},{"key":"24029_CR16","doi-asserted-by":"publisher","first-page":"100333","DOI":"10.1016\/j.lansea.2023.100333","volume":"21","author":"R Sharma","year":"2024","unstructured":"Sharma R, Abbastabar H, Abdulah DM, Abidi H, Abolhassani H, Abrehdari-Tafreshi Z, et al. Temporal patterns of cancer burden in Asia, 1990\u20132019: a systematic examination for the Global Burden of Disease 2019 study. Lancet Regional Health - Southeast Asia. 2024;21:100333.","journal-title":"Lancet Regional Health - Southeast Asia"},{"key":"24029_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.955358","volume":"12","author":"SA Nejadghaderi","year":"2022","unstructured":"Nejadghaderi SA, Moghaddam SS, Azadnajafabad S, Rezaei N, Rezaei N, Tavangar SM, et al. Burden of thyroid cancer in North Africa and Middle East 1990\u20132019. Front Oncol. 2022;12: 955358.","journal-title":"Front Oncol"},{"key":"24029_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221090012","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Huang Y, He X, Han C, Wu W, Shen H, et al. The global burden of thyroid cancer in high-income Asia-Pacific: a systematic analysis of the Global Burden of Disease study. Ther Adv Endocrinol Metab. 2022;13: 20420188221090012.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"24029_CR19","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health. 2023;11(2):e197\u2013206.","journal-title":"Lancet Glob Health"},{"key":"24029_CR20","unstructured":"International Agency for Research on Cancer. Data and methods \u2014 GLOBOCAN 2020. Cancer today: global cancer observatory. Lyon: IARC; 2020."},{"key":"24029_CR21","unstructured":"United Nations Development Programme. Human Development Index (HDI). Human Development Reports \u2014 Data Center; 2022."},{"key":"24029_CR22","unstructured":"World Health Organization. Current health expenditure (CHE) as percentage of gross domestic product (GDP) (%). Global Health Observatory data repository; 2022."},{"issue":"10062","key":"24029_CR23","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","volume":"388","author":"GA Stevens","year":"2016","unstructured":"Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Lancet. 2016;388(10062):e19\u201323.","journal-title":"Lancet"},{"issue":"12","key":"24029_CR24","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495\u20139.","journal-title":"Int J Surg"},{"issue":"10","key":"24029_CR25","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/cncr.29228","volume":"121","author":"V Sunkara","year":"2015","unstructured":"Sunkara V, H\u00e9bert JR. The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care. Cancer. 2015;121(10):1563\u20139.","journal-title":"Cancer"},{"key":"24029_CR26","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2023."},{"key":"24029_CR27","doi-asserted-by":"publisher","first-page":"f4706","DOI":"10.1136\/bmj.f4706","volume":"347","author":"JP Brito","year":"2013","unstructured":"Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ. 2013;347:f4706.","journal-title":"BMJ"},{"key":"24029_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10091621","author":"D Horgan","year":"2022","unstructured":"Horgan D, F\u00fchrer-Sakel D, Soares P, Alvarez CV, Fugazzola L, Netea-Maier RT, et al. Tackling thyroid cancer in Europe-the challenges and opportunities. Healthcare. 2022. https:\/\/doi.org\/10.3390\/healthcare10091621.","journal-title":"Healthcare"},{"issue":"9","key":"24029_CR29","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/ijc.31884","volume":"144","author":"J Lortet-Tieulent","year":"2019","unstructured":"Lortet-Tieulent J, Franceschi S, Dal Maso L, Vaccarella S. Thyroid cancer \u201cepidemic\u201d also occurs in low- and middle-income countries. Int J Cancer. 2019;144(9):2082\u20137.","journal-title":"Int J Cancer"},{"issue":"9","key":"24029_CR30","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/bjc.2016.304","volume":"115","author":"CR Smittenaar","year":"2016","unstructured":"Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer incidence and mortality projections in the UK until 2035. Br J Cancer. 2016;115(9):1147\u201355.","journal-title":"Br J Cancer"},{"issue":"3","key":"24029_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1089\/thy.2013.0257","volume":"24","author":"R Udelsman","year":"2014","unstructured":"Udelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds. Thyroid. 2014;24(3):472\u20139.","journal-title":"Thyroid"},{"issue":"4","key":"24029_CR32","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/hed.25029","volume":"40","author":"A Sanabria","year":"2018","unstructured":"Sanabria A, Kowalski LP, Shah JP, Nixon IJ, Angelos P, Williams MD, et al. Growing incidence of thyroid carcinoma in recent years: factors underlying overdiagnosis. Head Neck. 2018;40(4):855\u201366.","journal-title":"Head Neck"},{"issue":"12","key":"24029_CR33","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3346\/jkms.2012.27.12.1491","volume":"27","author":"TJ Lee","year":"2012","unstructured":"Lee TJ, Kim S, Cho HJ, Lee JH. The incidence of thyroid cancer is affected by the characteristics of a healthcare system. J Korean Med Sci. 2012;27(12):1491\u20138.","journal-title":"J Korean Med Sci"},{"issue":"30","key":"24029_CR34","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1200\/JCO.2016.67.7419","volume":"34","author":"L Furuya-Kanamori","year":"2016","unstructured":"Furuya-Kanamori L, Bell KJL, Clark J, Glasziou P, SAR. SAR Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol. 2016;34(30):3672\u20139.","journal-title":"J Clin Oncol."},{"issue":"4","key":"24029_CR35","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.amjsurg.2009.11.008","volume":"200","author":"LG Morris","year":"2010","unstructured":"Morris LG, Myssiorek D. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg. 2010;200(4):454\u201361.","journal-title":"Am J Surg"},{"issue":"11","key":"24029_CR36","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S2213-8587(24)00223-7","volume":"12","author":"M Li","year":"2024","unstructured":"Li M, Dal Maso L, Pizzato M, Vaccarella S. Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013\u201317 in 63 countries worldwide: a population-based study. Lancet Diabetes Endocrinol. 2024;12(11):824\u201336.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"24029_CR37","first-page":"585","volume":"19","author":"BL Sprague","year":"2008","unstructured":"Sprague BL, Andersen WS, Trentham-Dietz A. Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes Control. 2008;19(6):585\u201393.","journal-title":"Cancer Causes Control"},{"key":"24029_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.coemr.2023.100472","volume":"31","author":"Q-L Tran","year":"2023","unstructured":"Tran Q-L, Davies L. Thyroid cancer incidence differences between men and women. Curr Opin Endocr Metab Res. 2023;31: 100472.","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"10","key":"24029_CR39","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1001\/jamainternmed.2021.4804","volume":"181","author":"K LeClair","year":"2021","unstructured":"LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO, Davies L. Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex in US thyroid cancer incidence compared with a meta-analysis of subclinical thyroid cancer rates at autopsy. JAMA Intern Med. 2021;181(10):1351\u20138.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"24029_CR40","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S2213-8587(20)30115-7","volume":"8","author":"M Li","year":"2020","unstructured":"Li M, Dal Maso L, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8(6):468\u201370.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"24029_CR41","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1089\/thy.2015.0116","volume":"25","author":"S Vaccarella","year":"2015","unstructured":"Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S. The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. Thyroid. 2015;25(10):1127\u201336.","journal-title":"Thyroid"},{"issue":"2","key":"24029_CR42","doi-asserted-by":"publisher","first-page":"E276","DOI":"10.1210\/jc.2013-2503","volume":"99","author":"CK Jung","year":"2014","unstructured":"Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99(2):E276\u201385.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"24029_CR43","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/obr.12321","volume":"16","author":"D Schmid","year":"2015","unstructured":"Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes Rev. 2015;16(12):1042\u201354.","journal-title":"Obes Rev"},{"issue":"8","key":"24029_CR44","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/jnci\/djz202","volume":"112","author":"CM Kitahara","year":"2020","unstructured":"Kitahara CM, Pfeiffer RM, Sosa JA, Shiels MS. Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995\u20132015). J Natl Cancer Inst. 2020;112(8):810\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"24029_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1133098","volume":"14","author":"L Xu","year":"2023","unstructured":"Xu L, Cao ZX, Weng X, Wang CF. Global thyroid cancer incidence trend and age-period-cohort model analysis based on Global Burden of Disease Study from 1990 to 2019. Front Endocrinol (Lausanne). 2023;14: 1133098.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9957","key":"24029_CR46","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/S0140-6736(14)62242-X","volume":"384","author":"JH Lee","year":"2014","unstructured":"Lee JH, Shin SW. Overdiagnosis and screening for thyroid cancer in Korea. Lancet. 2014;384(9957):1848.","journal-title":"Lancet"},{"issue":"8","key":"24029_CR47","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1210\/clinem\/dgaa192","volume":"105","author":"C Panato","year":"2020","unstructured":"Panato C, Vaccarella S, Dal Maso L, Basu P, Franceschi S, Serraino D, et al. Thyroid cancer incidence in India between 2006 and 2014 and impact of overdiagnosis. J Clin Endocrinol Metab. 2020;105(8):2507\u201314.","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"24029_CR48","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1111\/1759-7714.14099","volume":"12","author":"WQ Bao","year":"2021","unstructured":"Bao WQ, Zi H, Yuan QQ, Li LY, Deng T. Global burden of thyroid cancer and its attributable risk factors in 204 countries and territories from 1990 to 2019. Thorac Cancer. 2021;12(18):2494\u2013503.","journal-title":"Thorac Cancer"},{"issue":"7","key":"24029_CR49","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/cam4.3823","volume":"10","author":"S Azadnajafabad","year":"2021","unstructured":"Azadnajafabad S, Saeedi Moghaddam S, Mohammadi E, Rezaei N, Ghasemi E, Fattahi N, et al. Global, regional, and national burden and quality of care index (QCI) of thyroid cancer: a systematic analysis of the Global Burden of Disease Study 1990\u20132017. Cancer Med. 2021;10(7):2496\u2013508.","journal-title":"Cancer Med"},{"issue":"2","key":"24029_CR50","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12020-023-03604-3","volume":"84","author":"L Scappaticcio","year":"2024","unstructured":"Scappaticcio L, Trimboli P, Bellastella G, Ferrazzano P, Clery E, Cozzolino I, et al. Prediction of classical versus non classical papillary thyroid carcinoma subtypes from cytology of nodules classified according to TIRADS. Endocrine. 2024;84(2):560\u201370.","journal-title":"Endocrine"},{"issue":"4","key":"24029_CR51","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41591-022-01738-x","volume":"28","author":"CS Pramesh","year":"2022","unstructured":"Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, Dare AJ, et al. Priorities for cancer research in low- and middle-income countries: a global perspective. Nat Med. 2022;28(4):649\u201357.","journal-title":"Nat Med"},{"issue":"6","key":"24029_CR52","first-page":"563","volume":"112","author":"EP Mitchell","year":"2020","unstructured":"Mitchell EP. Declines in cancer screening during COVID-19 pandemic. J Natl Med Assoc. 2020;112(6):563\u20134.","journal-title":"J Natl Med Assoc"},{"issue":"6","key":"24029_CR53","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1470-2045(20)30242-4","volume":"21","author":"D Jones","year":"2020","unstructured":"Jones D, Neal RD, Duffy SRG, Scott SE, Whitaker KL, Brain K. Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. Lancet Oncol. 2020;21(6):748\u201350.","journal-title":"Lancet Oncol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24029-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-24029-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24029-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:15:43Z","timestamp":1759234543000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-24029-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24029"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-24029-9","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3201"}}